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„Look-alike, sound-alike‟ medicines are associated with dispensing errors. This 
commentary aims to fuel discussion surrounding how drug name nomenclature and similar 
packaging between medicines can lead to selection errors, the need for enhanced approval 
systems for medicine names and packaging, and best practice „solutions‟. The literature 
reveals a number of environmental risks and human factors that can contribute to such 
errors. To contextualise these risks, we interviewed 13 quality and safety experts, 
psycholinguists, and hospital and community pharmacy practitioners in Australia, and 
commissioned a medical software industry expert to conceptualise electronic initiatives. 
Environmental factors contributing to such errors, identified through both the literature and 
interviews, include distractions during dispensing; workflow controls should minimise the 
„human factors‟ element of errors. Technological solutions with some support, and yet 
recognised limitations, include font variations, automated alerts, barcode scanning and real-
time reporting programmed into dispensing software; further development of these 




Accuracy in the dispensing of medicines is vital for patient safety. A major contributor to 
dispensing errors is “look-alike and sound-alike” (LASA) medicines (Figure 1)
1
. Around 
one in four medication errors has been attributed to orthographic (look-alike) and phonetic 
(sound-alike) similarity between drug names and/or confusable packaging
2-5
. Of concern is 
that these errors have in common a human element, and are preventable through vigilance 
and understanding of their root cause. 
 
In this commentary, we draw attention to risk factors and call for further research into risk-
reduction initiatives. Our review of the literature was supplemented with findings from 
semi-structured interviews with four clinical governance experts, four hospital pharmacy 
practitioners with experience in medicines safety initiatives, two community pharmacists, 
two psycholinguists and a quality and safety administrator in Australia. Participants were 
purposively selected to explore their experiences and opinions regarding a) risk situations 
in the selection of medicines during dispensing or administration processes and b) 
initiatives to reduce the identified risks. A representative from the Medical Software 
Industry Association reviewed the interview summary and provided expert opinion on the 
feasibility of technological „solutions‟. Presented below is a reflection that integrates the 
interview data (identifying the participants by their area of practice) with reports from 
published literature, where available, to provide an overview of the problems associated 
with LASA medicines. 
 
Risks Relating to Drug Nomenclature and Packaging 
A dominant drug name within a „neighbourhood‟ of names familiar to an individual, and 
the „density‟ of this neighbourhood (the number of competing similar names), can interfere 
with identification of the required medicine (clinical governance interviewee). A related 
issue is „confirmation bias‟, whereby familiarity with a patient‟s history and the medicines 
commonly prescribed by certain doctors can result in erroneous assumptions 
(psycholinguistics). Confusion is more likely if the medicines appear in the same context 
(psycholinguistics). A notable example exists with „Z-drugs‟ (the hypnotics zolpidem and 
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zopiclone) marketed in close succession (community pharmacy). An added complication in 
Australia arises from the many generic „brands‟ marketed (clinical governance); dispensers 
might wrongly assume that they know the brand name of the generic alternative 
(community pharmacy). 
 
These insights have implications for approval of drug names in Australia. There is potential 
to automate screening to identify proposed names that are orthographically and/or 
phonetically similar to existing medicines, as implemented by United States Food and Drug 
Administration (clinical governance). „Uniqueness‟ of medicine names can be improved by 
the distinguishing syllable(s) being at the start or middle of medicine names. Longer 
medicine names can increase the risk of confusion, yet the shorter the name, the greater the 
chance of similarity to existing names (psycholinguistics). 
 
Risks for drug name confusion are confounded by the availability of different medicines in 
similar strengths, pack sizes, colours and dosage forms, and their use for similar conditions 
(clinical governance). Pharmacists face many medicines packaged in white bottles or 
boxes, unless different coloured caps or other distinguishing markers are used, and 
packaging updates might not be recognised (community pharmacy). Optimal design of 
manufacturers‟ labels has been explored in Denmark (www.e-types.dk/39267.9000/), with 
recommendations for font contrasts, legibility and layout; this appears to have merit for 
international application (quality and safety).  
 
Errors during Dispensing Processes  
 
Review of the international clinical literature and individual case reports reveals that 
misidentification of medicines may arise from the misreading of computer-printed or 
handwritten prescriptions or medication orders, mishearing of a spoken medicine name, 
wrong selection of similar-looking medicine names from lists in dispensing software, or 
wrong selection of a medicine from the shelf, either due to similar packaging or 
misidentification of the name
6,7,9-11
. Particular attention should be paid to selecting 
medicines from lists (community pharmacy); confusion may arise when selecting from lists 
if the eye focuses on the start and end of a medicine name, not recognising a distinguishing 
syllable mid-word (psycholinguistics). 
 
Factors contributing to these errors include chaos and interruptions (community pharmacy, 
psycholinguistics). Such distractions lengthen the time that a medicine name must be held 
in one‟s working memory, to the critical point of “lose it or confuse it” (psycholinguistics). 
Best practice would dictate returning to the previous step if dispensing is interrupted, and 
separation of dispensing and checking processes (community pharmacy), perhaps utilising 
dispensing technicians, with pharmacists undertaking responsibility for the final check 
(medical software). 
 
Pronunciation of the drug out loud may ensure effective reading of its name and retention 
in one‟s working memory (psycholinguistics). Similarly, verbal prescriptions should be 
repeated to the prescriber, including spelling out the medicine name
8
. People with difficulty 
pronouncing long medicine names are probably at a greater risk of confusing LASA 
medicines (psycholinguistics).  
 
Locum pharmacists may be unfamiliar with the dispensing system in a pharmacy or with 
the dispensary layout, resulting in „picking‟ errors particularly under time pressure 
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(community pharmacy). Separation of confusable medicines on the shelf
 
prompts the 
dispenser to search for the required medicine (community pharmacy). This is consistent 
with published recommendations
8
, although signposting of the shelf locations should be 
used strategically to avoid „alert fatigue‟ (community pharmacy). In one hospital, LASA 
medicines have been identified with additional yellow labels under their regular labels. 
Other hospital pharmacy initiatives have been the arrangement of medicines by generic 
names, with laminated warning signs to mark commonly confused LASA medicines 
(hospital pharmacy). Practical suggestions reported in the literature also include limiting 
hospital formularies, eliminating abbreviations and encouraging patients to question 
physical changes in their medications
12
. The need for “system-based strategies” to prevent 
these errors has been recognised
8,13
, and there is potential for research at various levels to 
investigate the acceptability and outcomes of these initiatives. 
 
Other environmental risks are inadequate lighting, illegible handwriting, and lack of 
familiarity with variations in generic and/or brand names of medicines and packaging, 
particularly small labels on ampoules or vials
1,6-8
. It is recommended that dispensing staff 
familiarise themselves with medicine names and packaging on an “internal” level, i.e. get to 




Four „technological solutions‟ integrated into dispensing systems have been identified, with 
mixed support in the literature and amongst the interviewees: 
 
1. Font variation. This involves manipulation of written text to highlight the 
distinguishing syllable(s) or characters between similar drug names, as in Tall Man 
lettering (Figure 2)
14
. Research has involved limited numbers of subjects and 
experimental exercises in either field or laboratory conditions, and in some instances, 
using lay subjects, with equivocal error reduction but positive acceptability data
11,15-17
. 
Theoretically, Tall Man lettering should enhance dispensing accuracy (hospital 
pharmacy, clinical governance, quality and safety) and have an educative function
17
. 
However, concerns are that: 
a. Mixed-case lettering may increase error rates if it interferes with the reading of a 
medicine name (psycholinguistics) or prolongs reading time (hospital pharmacy). 
This equates to “destroying” a word shape.
7
 
b. If Tall Man lettering induces an upper-case first letter for a generic medicine, this 
may give the appearance of a brand name (psycholinguistics).  
c. A number of medicines may not be adequately distinguished using Tall Man lettering 











d. Without national guidelines, Tall Man lettering could be overused or used 
inconsistently (clinical governance, quality and safety). Restriction to a small 
percentage of confusable medicines, and at the point during dispensing where 
medicines are selected from lists (hospital pharmacy, medical software), were 
suggested.  
e. Some flexibility would be warranted to allow dispensing staff to contribute actual and 






Despite these concerns and lack of conclusive data, Tall Man lettering has potential for 
use in electronic selection menus, shelf labels and dispensing labels (clinical 
governance, medical software). This would be a relatively low-cost initiative, and a 
number of organisations are well positioned to collaboratively develop, manage and 
monitor this initiative (medical software).  
 
2. Automated alerts during dispensing of LASA medicines. This is not a new concept, but 
further development is recommended. All major dispensing software in Australia 
incorporates warnings of various types, which originate from Australia‟s major 
pharmacy indemnity organisation, Pharmaceutical Defence Limited, in collaboration 
with software vendors. Some systems allow pharmacists to add alerts, and vary how the 
operator acknowledges the warnings (medical software). Mixed support has been 
reported.
5,8,19,20
 The key concern is “alert fatigue” (clinical governance, community 
pharmacy), so use should be strategic and guided by risk assessment (clinical 
governance), and there is potential for further manipulation of the alerts to optimise their 
effectiveness (medical software). 
 
3. Barcode scanners to confirm drug selection against the medicine selected on the 
dispensing screen.
8
 This development has been generally accepted in community 
pharmacy in Australia, where financial incentives have been made available to purchase 
the hardware (medical software). Barcode scanning should theoretically eliminate most 
errors if used appropriately. However, reliance on scanning may merely “relocate” 
human factors problems rather than obviate them, and perpetuate prior errors. Manual 
checking procedures are still required to detect cases of erroneous data entry (community 
pharmacy, clinical governance). Further, there was concern that the use of barcode 
scanners may reduce the impact of other initiatives to reduce LASA risks (clinical 
governance). 
4. Real-time reporting. Awareness of the risks of misidentification of medicines may be 
improved by case reporting by health professionals, with near-miss and error reporting 
incorporated electronically into dispensing software (medical software). Hospitals use 
electronic incident recording systems for documentation of LASA medicine errors 
(hospital pharmacy). In community pharmacy, software vendors release monthly 




Many risks for LASA errors have origins beyond the practice environment (e.g. drug 
nomenclature and similar packaging of medicines), and ideally would be reduced during 
pre-marketing approvals of medicines. Accepting that some degree of similarity will always 
exist between drug names and between product packaging, we also draw attention to risk 
reduction at the practice level, where it should be noted that all errors have a „human‟ 
element, such as making assumptions, failure to correctly hear or visually check, and 
distractions relating to fatigue and/or a busy work environment. These types of errors 
should not occur in ideal work practices. Human factors associated with errors were 
explored using psycholinguistics principles, revealing interesting phenomena regarding 
how the brain registers, processes and stores words (names of medicines) and images (pack 
shapes and characteristics), and how font variations and environmental influences 




We recognise that the field of psycholinguistics is much more extensive than the insights 
reported here, and that there is potential to further involve this science in trials of word and 
packaging design. Further, the limited number of interviewees does not aim to be 
representative of the full spectrum of pharmacy practice, and merely serves to explore 
issues from a number of perspectives. It should be noted, though, that the majority of 
literature on this topic stems from individual case reports, so we believe that integrating the 
experiences of interviewees with the literature is a legitimate approach to expand this topic. 
Our focus has been on errors during dispensing. The numerous other stages of the 
medication cycle, from dispensing through to administration of doses, offer many avenues 
for research into risk-reduction strategies. Indeed, the need for further user studies 




Together, review of the literature, the series of key informant interviews and 
conceptualisation of electronic initiatives have given rise to a number of practice-based 
recommendations and technological „solutions‟ that may be used individually or in a multi-
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Figure 1: Examples of LASA Medicines 
 
Losec (omeprazole) Prozac (fluoxetine) 
Aropax (paroxetine) Aratac (amiodarone) 
Zocor (simvastatin) Zoton (lansoprazole) 
Mogadon (nitrazepam) Maxolon (metoclopramide) 
Xanax (alprozolam) Zantac (ranitidine) 
Diflucan (fluconazole) Diprivan (propofol) 
Carafate (sucralfate) Caltrate (calcium) 
 
 





Contrast Hydroxyzine Hydralazine 
Weight Hydroxyzine Hydralazine 
Case (Tallman) HydrOXYzine HydrALAzine 
 
 
